Acelyrin, Inc. Stock
Stocks
SLRN
US00445A1007
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.270 USD | +1.79% |
|
-.--% | - |
| 23/05/25 | Acelyrin, Inc.(NasdaqGS:SLRN) dropped from S&P TMI Index | CI |
| 23/05/25 | Acelyrin, Inc.(NasdaqGS:SLRN) dropped from S&P Global BMI Index | CI |
| Market Cap | 229M 200M 185M 173M 325M 21.66B 327M 2.2B 856M 10.65B 860M 842M 36.99B | P/E 2023 |
-1.37x | P/E 2024 | -1.26x |
|---|---|---|---|---|---|
| Enterprise Value | -211M -185M -171M -159M -299M -19.98B -302M -2.03B -790M -9.82B -794M -777M -34.12B | EV / Sales 2023 |
-
| EV / Sales 2024 | - |
| Free-Float |
84.72% | Yield 2023 * |
-
| Yield 2024 | - |
| 1 day | +1.79% |
| 3 years | 1.84 |  | 29.88 |
| 5 years | 1.84 | | 29.88 |
| 10 years | 1.84 | | 29.88 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 21/05/25 | Issuer sale | Director | 285,851 | 0.2839% | ||
| 21/05/25 | AyurMaya Capital Management Co. LP
| Issuer sale | Company | 9,334,735 | 9.2696% | |
| 21/05/25 | Issuer sale | Chairman | 298,835 | 0.2968% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.79% | -.--% | -.--% | -88.42% | 229M | |
| +0.68% | +6.03% | +71.97% | +120.65% | 56.65B | |
| +4.00% | +7.51% | +63.67% | +68.77% | 47.49B | |
| -0.77% | -0.67% | -15.34% | -15.95% | 22.81B | |
| +2.93% | +1.17% | -3.97% | +384.78% | 21.37B | |
| +1.30% | +3.73% | +27.10% | -17.51% | 16.12B | |
| +1.62% | +8.32% | +24.58% | -35.62% | 15.56B | |
| -1.08% | -3.11% | +27.20% | +158.30% | 12.91B | |
| +3.30% | +15.02% | +133.24% | +273.89% | 12.86B | |
| +1.43% | -6.44% | +21.49% | - | 11.67B | |
| Average | +1.64% | +1.94% | +34.99% | +94.32% | 21.77B | |
| Weighted average by Cap. | +1.80% | +3.27% | +45.03% | +110.05% |
| 2023 | 2024 | |
|---|---|---|
| Net sales | - | - |
| Net income | -382M -333M -308M -288M -540M -36.07B -544M -3.67B -1.43B -17.73B -1.43B -1.4B -61.6B | -248M -217M -201M -187M -352M -23.46B -354M -2.38B -928M -11.53B -932M -912M -40.07B |
| Net Debt | -720M -629M -582M -543M -1.02B -68.03B -1.03B -6.91B -2.69B -33.45B -2.7B -2.64B -116B | -441M -385M -356M -332M -624M -41.64B -629M -4.23B -1.65B -20.47B -1.65B -1.62B -71.11B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- SLRN Stock
Select your edition
All financial news and data tailored to specific country editions
